Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma

On August 19, 2021

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Boeing, NASA Complete First Starliner Space Station Flight Test

Northrop Grumman Australia Announces Tech Showcase Winners

IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022